Jason Rhodes is a Partner at Atlas Venture and focuses on the creation, development and business strategy of novel therapeutics companies. He is a founder and the chairman, and previously acting CEO, of Generation Bio, and a founder, the chairman and currently acting CEO of Disarm Therapeutics, and a member of the board of directors of Replimune, Gemini Therapeutics, Accent Therapeutics, and Bicycle Therapeutics. Prior to joining Atlas in 2014, Jason was President of Epizyme, Inc. (NASDAQ: EPZM), a public biopharmaceutical company. Prior to Epizyme, Jason led business development at Alnylam (NASDAQ: ALNY). Prior to Alnylam, Jason was a founder and partner with Fidelity Biosciences (now F-Prime Capital Partners), the life sciences venture capital arm of Fidelity Investments. He holds a BA from Yale University and an MBA from the Wharton School of the University of Pennsylvania.